Brintellix

Brintellix Dosage/Direction for Use

vortioxetine

Manufacturer:

Lundbeck

Distributor:

Metro Drug
Full Prescribing Info
Dosage/Direction for Use
Posology (tablet): The starting and recommended dose of Brintellix (Vortioxetine hydrobromide) is 10 mg Vortioxetine once daily.
Depending on individual patient response, the dose may be increased to a maximum of 20 mg Vortioxetine once daily or decreased to a minimum of 5 mg Vortioxetine once daily.
After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response.
Treatment discontinuation: Patients treated with Brintellix can abruptly stop taking the medicinal product without the need for a gradual reduction in dose (see Pharmacology: Pharmacodynamics under Actions).
Special population: Elderly patients: The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥65 years of age. Caution is advised when treating patients ≥65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited (see Precautions).
Special population: Cytochrome P450 inhibitors: Depending on individual patient response, a lower dose of vortioxetine may be considered if strong CYP2D6 inhibitors (e.g. bupropion, quinidine, fluoxetine, paroxetine) are added to Brintellix treatment (see Interactions).
Special population: Cytochrome P450 inducers: Depending on individual patient response, a dose adjustment of vortioxetine may be considered if a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) is added to Brintellix (Vortioxetine hydrobromide) treatment (see Interactions).
Special population: Paediatric population: The safety and efficacy of Brintellix in children and adolescents aged less than 18 years have not been established. No data are available (see Precautions).
Method of administration: Brintellix (Vortioxetine hydrobromide) is for oral use. The film-coated tablets can be taken with or without food.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in